Please ensure Javascript is enabled for purposes of website accessibility

Why BioXcel Therapeutics Stock Is Plunging Today

By Prosper Junior Bakiny - Apr 1, 2021 at 2:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not impressed with the biotech's latest clinical update.

What happened

Shares of BioXcel Therapeutics (BTAI 6.15%) are trading lower on Thursday after the company reported somewhat disappointing data from a clinical trial for one of its leading pipeline candidates, BXCL501, on Wednesday evening. The biotech's stock was down by 13.3% as of 2:31 p.m. EDT.

So what 

BXCL501 is a thin sublingual film being developed for the treatment of opioid withdrawal symptoms, among other conditions. In a phase 1b/2 study, BXCL501 was generally safe and well tolerated with no serious adverse reaction reported, which was the study's primary safety endpoint. However, it is worth noting that treatment adverse events were relatively frequent for the two highest doses of BXCL501 (180 micrograms and 240 micgrograms), at least when compared to the placebo, which recorded no treatment adverse events.

Doctor giving a thumbs down.

Image source: Getty Images.

One of the study's secondary endpoints was an improvement in retention rates, which is a key goal of opioid withdrawal treatment. The 120 microgram and 180 microgram dose groups showed 42% and 52% retention rates, respectively, six days after treatment with BXCL501, compared to a 24% retention rate for the placebo group. However, these observations were not statistically significant. These mixed results prompted Truist analyst Robyn Karnauskas to lower her price target for BioXcel stock to $127, down from $150, although the analyst kept a buy rating on the shares. Given that BioXcel is currently trading for $37.39, it is clear that Karnauskas still sees a significant upside for the biotech stock

Now what

BXCL501 is also being developed as a treatment for acute agitation associated with psychiatric conditions such as schizophrenia and bipolar disorder. The therapy could generate more than a billion dollars in sales from these indications, provided it earns regulatory approval. In other words, despite the relatively unimpressive results from this early stage study of BXCL501 as a treatment for opioid withdrawal symptoms, the medicine could still have a bright future ahead. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioXcel Therapeutics, Inc. Stock Quote
BioXcel Therapeutics, Inc.
BTAI
$12.25 (6.15%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.